Lenacapavir HIV Prevention: Approval and Access Strategy Updates

By Rene Pretorius

February 21, 2025

Gilead Sciences has submitted marketing authorization applications to the European Medicines Agency (EMA) for lenacapavir HIV prevention, a twice-yearly injectable pre-exposure prophylaxis (PrEP) for HIV prevention. This marks a critical step in expanding prevention options.

Regulatory Submissions and Fast-Track Review for Lenacapavir

Gilead filed two applications:

  • A Marketing Authorization Application (MAA) to the European Commission for lenacapavir as PrEP.
  • An EU-Medicines for All (EU-M4all) application, enabling faster approval in low- and lower-middle-income countries by leveraging the EU’s assessment.

The EMA will conduct a parallel Accelerated Assessment, recognizing lenacapavir´s potential public health impact and therapeutic innovation.

Clinical Evidence and Safety of Lenacapavir

The submissions rely on data from Phase 3 PURPOSE 1 and PURPOSE 2 trials:

  • PURPOSE 1: Zero HIV infections among cisgender women in the lenacapavir HIV prevention group, showing 100% risk reduction compared to background HIV incidence (bHIV).
  • PURPOSE 2: Lenacapavir HIV prevention achieved a 96% risk reduction among cisgender men and gender-diverse individuals, outperforming daily oral Truvada (TDF/FTC). Only two infections occurred among 2,180 participants on lenacapavir.

Both trials confirmed lenacapavir favorable safety profile, with no significant or new safety concerns reported.

U.S. Regulatory Status and Previous Approvals

Gilead also submitted New Drug Applications (NDAs) to the U.S. Food and Drug Administration (FDA) in December 2024 for PrEP. However, lenacapavir remains investigational for HIV prevention and is not yet globally approved.

Lenacapavir, marketed as Sunlenca, already has FDA approval for a different use. In 2023, the FDA approved it for adults with multi-drug resistant HIV-1, in combination with other antiretrovirals.

Expanding Global Access to Lenacapavir HIV Prevention

Gilead aims to accelerate lenacapavir’s regulatory approvals and ensure rapid availability in high-incidence regions. Its twice-yearly dosing could improve adherence compared to daily oral PrEP, offering a promising new tool in HIV prevention.

 

Reference url

Recent Posts

Paving the Way for Digital Health Technologies: NICE’s Bold New Strategy for the NHS

By HEOR Staff Writer

October 9, 2025

The National Institute for Health and Care Excellence (NICE) is expanding its technology appraisals programme, and starting April 2026, this will include digital health technologies that are placed on an equal legal footing with medicines in the NHS. This initiative forms part of the NHS 10-year ...
Health Misinformation Autism: The Dangers of Politicized Science in Vaccine and Drug Discourse

By João L. Carapinha

October 7, 2025

The BMJ article “Tylenol, vaccines, and autism: the medical mayhem of the MAGA methodologists” argues that political and ideological actors, notably aligned with the MAGA movement, are promoting health misinformation about autism, vaccines, and paracetamol. They amplify preliminary, misinterprete...
Empowering Innovation: Clinical Trials Reform Strategies by EMA for 2025

By João L. Carapinha

September 29, 2025

The recently published European Medicines Agency (EMA) article addresses the strategic targets for improving the clinical trials reform landscape in Europe. It emphasizes measures that foster innovation, collaboration, and efficiency in clinical research. The article outlines new priorities for 2...